THE EFFECTIVENESS OF ACB-IP 1.0 UNIVERSAL PATHOGEN FREE CONCENTRATED COCKTAIL CONVALESCENT PLASMA IN COVID-19 INFECTION

Article activity feed

1. 

   ScreenIT

   Mar 24, 2021

   SciScore for 10.1101/2021.03.05.21251413: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement

   Consent: Written informed consent was obtained from all patients or their first degree relatives, and the trial was conducted under the principles stated in the Declaration of Helsinki and Good Clinical Practice guidelines and approval of Acibadem University ethics committee (Approval No: 2020-06/02) Clinical information of the groups was obtained from the hospital’s electronic medical records. IRB: Written informed consent was obtained from all patients or their first degree relatives, and the trial was conducted under the principles stated in the Declaration of Helsinki and Good Clinical Practice guidelines and approval of Acibadem University ethics committee …

   SciScore for 10.1101/2021.03.05.21251413: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	Consent: Written informed consent was obtained from all patients or their first degree relatives, and the trial was conducted under the principles stated in the Declaration of Helsinki and Good Clinical Practice guidelines and approval of Acibadem University ethics committee (Approval No: 2020-06/02) Clinical information of the groups was obtained from the hospital’s electronic medical records. IRB: Written informed consent was obtained from all patients or their first degree relatives, and the trial was conducted under the principles stated in the Declaration of Helsinki and Good Clinical Practice guidelines and approval of Acibadem University ethics committee (Approval No: 2020-06/02) Clinical information of the groups was obtained from the hospital’s electronic medical records.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.
   Cell Line Authentication	not detected.

   Table 2: Resources

   Experimental Models: Cell Lines
   Sentences	Resources
   After one hour of incubation at room temperature, 10000 Vero cell/well is placed in a 96 Well Flat Bottom plate with 100 µl of complete DMEM (4% FBS + 1% PSA).	Vero suggested: None
   Software and Algorithms
   Sentences	Resources
   Endotoxin Analysis: The gel-clot technique is used for detecting or quantifying endotoxins (Division of Charles River Laboratories, Inc Lot: L4451L)	Charles River Laboratories suggested: (Charles River Laboratories, RRID:SCR_003792)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   Although the study has some limitations such as short follow-up time and small sample size, concluded that convalescent plasma may improve survival if given early onset of the disease. In the study conducted by Liu et al. 39 hospitalized patients with severe to life-threatening COVID-19, received convalescent plasma compared to a non-transfused control group. According to their results patients receiving convalescent plasma therapy had improved survival and supplementary oxygen requirements at Day 14 post-transfusion compared to non-transfused controls. Moreover, the authors recommend the transfusion of the convalescent plasma immediately after the hospitalization which supports the current study results.24 In a large retrospective study it was revealed that convalescent plasma treatment is a safe treatment option in COVID-19.25 These findings are in line with our results that either plasma products are safe in clinical usage. Conflicting with the above-mentioned studies, the beneficial effect of convalescent plasma could not be confirmed in SARS-CoV2 pneumonia patients in previous placebo-controlled trials.17, 26 The reason for the controversial result is explained with the lack of neutralizing antibody titer measurement of the donor plasma in the PLACID trial.17 Also, convalescent plasma was administered to the patients later than 3 days, contrary to what is recommended in the FDA report. FDA suggested in its report, that convalescent plasma transfusion can be effective wit...

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04769245	Recruiting	The Effectiveness of ACB-IP 1.0 Convalescent Plasma in COVID…

   ---

   Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
2. 

   Version published to 10.1101/2021.03.05.21251413 on medRxiv

   Mar 17, 2021